sunday 23 sEpTEMbEr - ehmtic 2012
sunday 23 sEpTEMbEr - ehmtic 2012
sunday 23 sEpTEMbEr - ehmtic 2012
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
58<br />
EHMTIC20I2<br />
European Headache and Migraine Trust International Congress<br />
Poster Programme<br />
contInued<br />
P197 OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized,<br />
placebo-controlled phase of PREEMPT<br />
Dodick, D. 1 ; Diener, H.C. 2 ; Turkel, C. 3 ; DeGryse, R. 3 ; Brin, M. 3<br />
1 2 3 Mayo Clinic Arizona, United States; University of Essen, United Kingdom; Allergan, United States<br />
P198 Transcutaneous Vagus Nerve Stimulation (tVNS) for headache prophylaxis: initial experience<br />
Magis, D.; Gérard, P.; Schoenen, J.<br />
University Department of Neurology, Belgium<br />
P199 OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received<br />
all 5 treatment cycles in PREEMPT<br />
Aurora, S.K. 1 ; Dodick, D.W. 2 ; DeGryse, R.E. 3 ; Turkel, C.C. 4<br />
1 2 Swedish Neuroscience Institute, Seattle, WA, United States; Mayo Clinic Arizona, Dept. of Neurology, Phoenix, AZ, United States;<br />
3 4 Allergan, Irvine, CA, United States; Allergan, Irvine, CA, United States<br />
P200 The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment<br />
cycle in the PREEMPT clinical program<br />
Silberstein, S. 1 ; Dodick, D.W. 2 ; DeGryse, R.E. 3 ; Lipton, R. 4 ; Turkel, C.C. 3<br />
1 2 3 Thomas Jefferson University, Philadelphia, PA, United States; Mayo Clinic Arizona, Phoenix, AZ, United States; Allergan, Irvine,<br />
CA, United States; 4Albert Einstein College of Medicine, Bronx, NY, United States<br />
P201 Acute Treatment Optimization for Migraine: Results of the American migraine Prevalence and Prevention<br />
(AMPP) study<br />
Lipton, R.B. 1 ; Manack, A.N. 2 ; Serrano, D. 3 ; Buse, D.C. 4<br />
1 2 Department of Neurology, Montefiore Medical Center, Bronx, New York, United States; Allergan, Inc., Irvine, California, United<br />
States; 3Vedanta Research, Chapel Hill, North Carolina, United States; 4Department of Neurology, Montefiore Medical Center,<br />
Bronx, New York, United States<br />
P202 Flunarizine is more effective than topiramate in patients with chronic migraine and medication<br />
overuse headache<br />
Gracia-Naya, M. 1 ; Hernando-quintana, N. 1 ; García-Gomara, M.J. 2 ; Sánchez-Valiente, S. 2 ; Ríos, C. 3 ;<br />
Santos- Lasaosa, S. 4 ; Mauri, J.A. 4 ; Artal-Roy, J. 1 ; Latorre-Jimenez, A.M. 5<br />
1 2 3 4 Hospital Miguel Servet, Spain; Hospital Royo Villanova, Spain; Hospital C. Barbastro, Spain; Hospital Clínico Zaragoza, Spain;<br />
5Hospital San Jorge. Huesca, Spain<br />
P203 The ideas of people referred to neurologists about managing their headaches: A qualitative study<br />
Nadeem, F.; Noble, A.; Ridsdale, L.; Morgan, M.<br />
Kings College London, United Kingdom<br />
P204 OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of<br />
patients without medication overuse<br />
Diener, H.C. 1 ; Dodick, D.W. 2 ; DeGryse, R.E. 3 ; Turkel, C.C. 4<br />
1 2 University of Essen, Dept. of Neurology, Essen, Germany; Mayo Clinic Arizona, Dept. of Neurology, Phoenix, AZ, United States;<br />
3 4 Allergan, Irvine, CA, United States; Allergan, Irvine, CA, United States<br />
P206 Sumatriptan and dihydroergotamine in proximal and distal human isolated coronary arteries<br />
Labruijere, S.; Ramirez Rosas, M.B.; De Vries, R.; Danser, A.H.J.; MaassenVanDenBrink, A.<br />
Erasmus Medical Center, Netherlands<br />
P207 Application and efficacy of levetiracetam in prophylactic treatment of migraine without aura<br />
Maykova, T.N.<br />
Hedache Center Kyiv, Ukraine
Change language